Evidence map›Paper›PMID 35664030›Full record

ArticlePrzeglad gastroenterologiczny2022

Histamine 2 receptor antagonists do not improve the outcomes of hospitalized COVID-19 patients.

Waseem Amjad, Faisal Kamal, Adnan Malik, Ritu Singh, Sultan Mahmood

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Przeglad gastroenterologiczny, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Waseem AmjadDepartment of Internal Medicine, Albany Medical Center, Albany, NY, USA.
Faisal KamalDepartment of Gastroenterology, University of Tennessee, Memphis, TN, USA.
Adnan MalikDepartment of Internal Medicine, Loyola University Medical Center, Chicago, IL, USA.
Ritu SinghDepartment of Internal Medicine, University of Indiana, Fort Wayne, IN, USA.
Sultan MahmoodDepartment of Gastroenterology, University at Buffalo, Buffalo, NY, USA.
Albany Medical Center Hospital · USJohns Hopkins University · USLoyola University Medical Center · USUniversity at Buffalo, State University of New York · USUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Some observational studies have demonstrated the benefit of famotidine in COVID-19-infected individuals. The preference of using an H Aim: To compare the outcomes of hospitalized patients who were taking H Material and methods: We conducted a retrospective review of patients admitted for COVID-19 infection from 1 March until 31 July 2020. We included 396 patients admitted during the study period. Of the total, 39 (9.8%) received H Results: The baseline characteristics and comorbid conditions were similar in both groups. The mean age was 57.79 ±17.36 years, 43.2% were female, and 48.7% were Caucasian. The common comorbid conditions included HTN (56.8%), obesity (44.4%), diabetes mellitus (38.6%), and coronary artery disease (30.1%). Smoking was more prevalent in the PPI group (42.5% vs. 18.2%, Conclusions: The H

Indexed as

coronavirus disease 2019H2 receptor blockerproton pump inhibitors

Identifiers

PMID35664030
PMCPMC9165339
OpenAlexW3185392821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.